Floatz logo

Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells

Therapy-Related Acute Myeloid Leukemia

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Therapy-Related Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells is also rated in:

acute erythroid leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →
acute megakaryoblastic leukemiaDormant
CCC
Indicative ·
52 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →